ArriVent BioPharma, Inc. Common Stock (AVBP)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 77
- Market Cap
- $1.4B
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
SentiSense also tracks daily options readings for ArriVent BioPharma, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
ArriVent BioPharma, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.